Compare Nano Dimension Ltd - ADR (NNDM) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nano Dimension Ltd - ADR vs 10X Genomics Inc — how do they compare? Nano Dimension Ltd - ADR trades at $1.48 (market cap $315.88M), while 10X Genomics Inc trades at $67.74 (market cap $8.77B). The key difference: 10X Genomics Inc is far larger — about 27.8× Nano Dimension Ltd - ADR's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Nano Dimension Ltd - ADR nearer its low. Which is the better fit depends on your goals.
| NNDM | TXG | |
|---|---|---|
Market Cap | $315.88M | $8.77B |
Sector | Technology | Health |
52-Week High | $2.14 | $67.29 |
52-Week Low | $1.21 | $11.34 |
Enterprise Value | -$88.96M | $8.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NNDM trades at $1.555, down 4.01% on the day, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $121M but a net loss of -$163M, reflecting a net margin of -135.18%. Recent strategic moves include appointing a new board member and cost-saving initiatives aimed at reducing cash burn by $25M annually. The balance sheet shows a strong cash position of $757.96M with minimal debt, but operating cash flow remains negative.
The outlook is cautious due to persistent losses and high cash burn, though asset sales and cost cuts may improve liquidity. Investment opportunity lies in the company's cash reserves and potential strategic shifts, but risks include ongoing operational losses and shareholder activism. The stock faces pressure from weak profitability and bearish technical trends.
TXG trades at $65.60, up 4.71% today, with a bullish technical signal and recent earnings beats. The stock shows improving fundamentals, with 2025 revenue at $642.82M and net loss narrowing to -$43.54M. Positive sentiment is driven by patent wins, Atera platform demand, and institutional interest, though valuation metrics like P/S of 13.58 and EV/EBITDA of 142.2 remain elevated.
Outlook is cautiously optimistic with upside potential from Atera execution, but risks include high valuation, persistent losses, and competitive pressures. Analyst consensus is mixed with a $50.56 price target below current levels, indicating near-term caution despite long-term growth prospects in genomics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
